Preliminary analysis shows CBO's American Health Future Act would see $81 billion more savings

8 October 2009

A US Congressional Budget Office analysis released yesterday estimates the America's Healthy Future Act would generate $81 billion more in savings and revenues over a decade than its $829 billion cost. This is within President Barack Obama's target of a $900 billion deficit-neutral health care reform bill.

The analysis also estimates that the bill would result in health insurance coverage for 94% of non-elderly US residents, up from 83%. The Finance Committee is expected to vote on the Bill this week and then the Senate leadership will begin merging it with health care legislation passed by the HELP Committee.

The analysis reflects the specifications posted on the Committee's web site on October 2, 2009, corrections posted on October 5, and additional clarifications provided by the staff of the committee through October 6. CBO and Joint Committee on Taxation's (JCT) analysis is preliminary in large part because the Chairman's mark, as amended, has not yet been embodied in legislative language.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical